The firm recently won an NIH grant to develop its instrument-free gonorrhea test, and is also developing a chlamydia assay with the long-term goal of making a combined CT/NG test.
The funding comes from a syndicate which includes all Series C investors and one new investor, Chinese assay developer Wondfo Biotech.
The test runs on the firm's high throughput platforms and has claims for extragenital samples in addition to traditional samples.
Solid MDx revenue growth was driven primarily by sales of Aptima women's health products on the Panther and Tigris platforms.
The test detects chlamydia, gonorrhea, and trichomonas from a single patient sample.
Diagnostic systems strength was driven by strong growth in molecular and installations in Western Europe .
Revenues from the company’s molecular diagnostics business grew 6 percent, driven by continued strength in sales of women's health products.
Genome sequences from Neisseria gonorrhoeae isolates from the UK provided insights into transmission and resistance patterns.
Under the agreement, Goffin will distribute SpeeDx's PlexPCR and ResistancePlus multiplex real-time PCR product lines in Benelux.
The firm increased its MDx revenues 7 percent from a year ago and beat the consensus Wall Street estimates on the top and bottom lines.
Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.
Some science companies will be taking part in next month's March for Science, Fortune reports.
In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.
Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.